Logo image of MRUS

MERUS NV (MRUS) Stock Fundamental Analysis

NASDAQ:MRUS - Nasdaq - NL0011606264 - Common Stock - Currency: USD

47.37  -0.26 (-0.55%)

After market: 47.37 0 (0%)

Fundamental Rating

3

Overall MRUS gets a fundamental rating of 3 out of 10. We evaluated MRUS against 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MRUS as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, MRUS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MRUS had negative earnings in the past year.
In the past year MRUS has reported a negative cash flow from operations.
MRUS had negative earnings in each of the past 5 years.
MRUS had a negative operating cash flow in each of the past 5 years.
MRUS Yearly Net Income VS EBIT VS OCF VS FCFMRUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

MRUS has a Return On Assets of -28.95%. This is in the better half of the industry: MRUS outperforms 69.98% of its industry peers.
With a decent Return On Equity value of -34.77%, MRUS is doing good in the industry, outperforming 75.49% of the companies in the same industry.
Industry RankSector Rank
ROA -28.95%
ROE -34.77%
ROIC N/A
ROA(3y)-27.83%
ROA(5y)-28.28%
ROE(3y)-39.23%
ROE(5y)-48.66%
ROIC(3y)N/A
ROIC(5y)N/A
MRUS Yearly ROA, ROE, ROICMRUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100

1.3 Margins

MRUS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRUS Yearly Profit, Operating, Gross MarginsMRUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K

More info and screens

8

2. Health

2.1 Basic Checks

MRUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MRUS has more shares outstanding
The number of shares outstanding for MRUS has been increased compared to 5 years ago.
MRUS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MRUS Yearly Shares OutstandingMRUS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
MRUS Yearly Total Debt VS Total AssetsMRUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

MRUS has an Altman-Z score of 12.18. This indicates that MRUS is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 12.18, MRUS belongs to the best of the industry, outperforming 88.63% of the companies in the same industry.
There is no outstanding debt for MRUS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 12.18
ROIC/WACCN/A
WACC7.09%
MRUS Yearly LT Debt VS Equity VS FCFMRUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

MRUS has a Current Ratio of 8.32. This indicates that MRUS is financially healthy and has no problem in meeting its short term obligations.
MRUS has a better Current ratio (8.32) than 73.53% of its industry peers.
MRUS has a Quick Ratio of 8.32. This indicates that MRUS is financially healthy and has no problem in meeting its short term obligations.
MRUS has a better Quick ratio (8.32) than 73.71% of its industry peers.
Industry RankSector Rank
Current Ratio 8.32
Quick Ratio 8.32
MRUS Yearly Current Assets VS Current LiabilitesMRUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for MRUS have decreased by -3.72% in the last year.
MRUS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -21.34%.
The Revenue has been growing slightly by 2.75% on average over the past years.
EPS 1Y (TTM)-3.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-239.53%
Revenue 1Y (TTM)-21.34%
Revenue growth 3Y13.65%
Revenue growth 5Y2.75%
Sales Q2Q%6.7%

3.2 Future

Based on estimates for the next years, MRUS will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.62% on average per year.
Based on estimates for the next years, MRUS will show a very strong growth in Revenue. The Revenue will grow by 58.03% on average per year.
EPS Next Y-27.78%
EPS Next 2Y-15.1%
EPS Next 3Y-9.11%
EPS Next 5Y13.62%
Revenue Next Year-18.23%
Revenue Next 2Y7.81%
Revenue Next 3Y19.27%
Revenue Next 5Y58.03%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MRUS Yearly Revenue VS EstimatesMRUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
MRUS Yearly EPS VS EstimatesMRUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MRUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRUS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRUS Price Earnings VS Forward Price EarningsMRUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRUS Per share dataMRUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A cheap valuation may be justified as MRUS's earnings are expected to decrease with -9.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.1%
EPS Next 3Y-9.11%

More info and screens

0

5. Dividend

5.1 Amount

MRUS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MERUS NV

NASDAQ:MRUS (2/21/2025, 8:00:01 PM)

After market: 47.37 0 (0%)

47.37

-0.26 (-0.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31 2024-10-31/bmo
Earnings (Next)03-04 2025-03-04/amc
Inst Owners105.59%
Inst Owner Change-95.08%
Ins Owners0.57%
Ins Owner Change-0.59%
Market Cap3.24B
Analysts87.83
Price Target88.8 (87.46%)
Short Float %11.56%
Short Ratio13.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-33.03%
Min EPS beat(2)-62.2%
Max EPS beat(2)-3.86%
EPS beat(4)1
Avg EPS beat(4)-18.99%
Min EPS beat(4)-62.2%
Max EPS beat(4)28.31%
EPS beat(8)4
Avg EPS beat(8)-13.15%
EPS beat(12)8
Avg EPS beat(12)5.85%
EPS beat(16)9
Avg EPS beat(16)0.81%
Revenue beat(2)1
Avg Revenue beat(2)15.95%
Min Revenue beat(2)-15.38%
Max Revenue beat(2)47.28%
Revenue beat(4)1
Avg Revenue beat(4)-0.57%
Min Revenue beat(4)-20.67%
Max Revenue beat(4)47.28%
Revenue beat(8)4
Avg Revenue beat(8)2.15%
Revenue beat(12)7
Avg Revenue beat(12)3.31%
Revenue beat(16)10
Avg Revenue beat(16)3.41%
PT rev (1m)0.07%
PT rev (3m)-2.18%
EPS NQ rev (1m)-3.62%
EPS NQ rev (3m)-2.02%
EPS NY rev (1m)0.78%
EPS NY rev (3m)0.16%
Revenue NQ rev (1m)7.58%
Revenue NQ rev (3m)7.07%
Revenue NY rev (1m)4.55%
Revenue NY rev (3m)7.45%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 90.25
P/FCF N/A
P/OCF N/A
P/B 4.61
P/tB 4.62
EV/EBITDA N/A
EPS(TTM)-3.9
EYN/A
EPS(NY)-3.96
Fwd EYN/A
FCF(TTM)-2.3
FCFYN/A
OCF(TTM)-2.27
OCFYN/A
SpS0.52
BVpS10.27
TBVpS10.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.95%
ROE -34.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.83%
ROA(5y)-28.28%
ROE(3y)-39.23%
ROE(5y)-48.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 71.22%
Cap/Sales 4.96%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.32
Quick Ratio 8.32
Altman-Z 12.18
F-Score4
WACC7.09%
ROIC/WACCN/A
Cap/Depr(3y)270.68%
Cap/Depr(5y)225.81%
Cap/Sales(3y)9.73%
Cap/Sales(5y)8.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-239.53%
EPS Next Y-27.78%
EPS Next 2Y-15.1%
EPS Next 3Y-9.11%
EPS Next 5Y13.62%
Revenue 1Y (TTM)-21.34%
Revenue growth 3Y13.65%
Revenue growth 5Y2.75%
Sales Q2Q%6.7%
Revenue Next Year-18.23%
Revenue Next 2Y7.81%
Revenue Next 3Y19.27%
Revenue Next 5Y58.03%
EBIT growth 1Y-41.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-66.88%
EBIT Next 3Y-25.36%
EBIT Next 5YN/A
FCF growth 1Y-0.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3%
OCF growth 3YN/A
OCF growth 5YN/A